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Abstract
Importance
The association between the use of hormonal contraceptive and pancreatic cancer among
premenopausal women has until now been unclear. This is the first study to investigate the
risk of pancreatic cancer in pre-menopausal women.
Objective
To determine whether hormonal contraception increases the risk of developing pancreatic
cancer in pre-menopausal women.
Design
A nationwide prospective cohort study followed all women in Denmark in the age range of
15–49 years without previous cancer or venous thrombosis from 1995 to 2014. The Danish
National Prescription Registry provided individually updated exposure information on use of
hormonal contraception. The Danish Cancer Registry provided cancer diagnoses, and the
Danish National Patient Register containing clinical diagnoses and surgical codes at dis-
charge from public and private hospitals.
Setting
Population-based cohort study.
Participants
All women living in Denmark aged 15–49 years at January 1st, 1995, and those subse-
quently reaching age 15 years up to December 31st, 2014 were eligible for the study.
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Data Availability Statement: Data from The
Danish Cancer Register (histologically verified
cancers since 1943) provided information on any
malignant disease; the National Health Register
containing clinical diagnoses and surgical codes at
discharge from public and private hospitals since
1976, and the National Birth Register information
about births since 1973. The National Register of
Medicinal Product Statistics contains details of
redeemed prescriptions for hormonal
contraception were linked using the personal
identification number. Data from the National
Results
Among 1.9 million women who were followed on average for 11.4 years, 235 pancreatic
cancers occurred. Compared to never users, ever users of any type of hormonal contracep-
tion had a relative risk (RR) of pancreatic cancer of 0.90 (95% confidence interval (CI) 0.68–
1.19). No overall association between duration of hormonal contraceptive use and pancre-
atic cancer risk was found. Neither was long-term use of hormonal contraception associated
with pancreas cancer, RR 0.83 (95% CI 0.47–1.50). The risk did not vary between users of
combined and progestogen-only products. All models were adjusted for age, completed or
ongoing education, polycystic ovary syndrome, endometriosis and among parous women;
parity, age at first birth, smoking and body mass index.
Conclusions and relevance
Compared to never users the risk of pancreatic cancer is not significantly higher among cur-
rent and recent users of contemporary hormonal contraception and does not vary between
users of combined and progestogen-only products. In conclusion, our study suggests no
risk of pancreatic cancer with use of any type of hormonal contraception.
Introduction
The worldwide incidence rate of pancreatic cancer is 10.9 per 100,000 women versus 13.9 per
100,000 men; and pancreatic cancer is relatively rare in young women [1]. However, the mor-
tality rate of pancreatic cancer is almost identical with its incidence rate [2], reflecting its high
case-fatality rate.
Sex-steroid hormone receptors have been detected in both normal and neoplastic human
pancreatic tissue [3]. Estrogen has been found to inhibit the growth of pre-neoplastic pancre-
atic lesions or transplanted pancreatic carcinoma in rats and progesterone may possess anti-
neoplastic properties [3]. The pancreas is not necessarily considered a target organ of sex ste-
roids, but various clinical and experimental findings demonstrate effects of progesterone on
pancreatic endocrine function due to progesterone receptors expressed in islet cells; and repro-
ductive factors possibly play a role in the etiology of pancreatic cancer. [4][5]. Today, approxi-
mately 140 million women worldwide or 13% of women aged 15–49 years use hormonal
contraception.[6] Thus, determining the relationship between use of hormonal contraception
and pancreatic cancer is important given the high prevalence of hormonal contraceptive use
and the high case-fatality rate of pancreatic cancer. A majority of previous studies on hormonal
contraception and pancreatic cancer have been case-control and cohort studies, and report no
association between use of oral contraception and risk of pancreatic cancer. [7–10][11–13]
[14–16][17]. However, one prospective cohort study of nearly 120,000 women followed over
14 years found that long-term users of hormonal contraception had a, statistically significant,
72% increased risk of pancreatic cancer compared to never use [3]. In this study, oral contra-
ception use was self-reported via questionnaires. Moreover, the inclusion of postmenopausal
women in the study population could cause bias with regards to the risk of pancreas cancer
due to the use of postmenopausal hormone therapy (HT). Some studies suggest that use of HT
decreases the risk or has no association to the risk of developing of panceatic cancer.[3,12][17]
Other studies suggest that postmenopausal women alone are at increased risk of pancreatic
cancer. [11] To ensure no bias caused by factors related to the postmenopausal age, we
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investigated the use of different types of contemporary hormonal contraception and the risk of
pancreatic cancer in a large cohort of pre-menopausal women.
Materials and methods
Data sources
Since 1960 all citizens in Denmark have had a personal identification number recorded in the
Civil Registry that holds records of age, death, and emigration. Data from The Danish Cancer
Register (containing histologically verified cancers since 1943) provided information on any
malignant disease; the Danish National Patient Register contains clinical diagnoses and surgi-
cal codes at discharge from public and private hospitals since 1976, and the National Birth
Register information about births since 1973. The National Register of Medicinal Product Sta-
tistics contains details of redeemed prescriptions for hormonal contraception and was linked
using the personal identification number as the key identifier. Data from the National Register
of Medicinal Product Statistics is considered complete from January 1, 1995 and this was
consequently the start date of this study. Data was stored and analyzed on servers at Statistics
Denmark. The unique personal identification numbers were encrypted ensuring anonymity
during the data analyses.
Study population
All women living in Denmark aged 15–49 years at January 1st, 1995, and those subsequently
reaching age 15 years up to December 31st, 2014 were eligible for the study.
Hormonal contraception
From the National Register of Medicinal Product Statistics, we obtained information on the
date of redeemed prescriptions, the specific Anatomical Therapeutic Chemical code, dose,
number of packages, defined daily doses, and route of administration (tablet, patch, IUD, etc.).
The use of hormonal contraception was updated daily, with women changing status at time of
cessation or switch in type of hormonal contraception used. Gaps between prescriptions of less
than 28 days were filled out prospectively.[18]
Hormonal contraceptive use was categorized as current or recent use (cessation within last
six months), previous use (cessation more than six months ago) or never use. The levonorges-
trel-intrauterine system (IUD) was used for four years, unless pregnancy or another hormonal
product was prescribed before the IUD expired.
Confounding factors
The National Birth Register and Statistics Denmark provided information on potential con-
founders; parity (0, 1, 2, 3, 4 or >4), age at first birth among parous women (<25, 25–30,>30
years), smoking status among parous women (yes, no, unknown; available since 1991), body
mass index among parous women (<18.5, 18.5–25, 25.1–30, >30, unknown; available since
2004) and completed or ongoing education (elementary school only, high school only, further
education but not college/university, college/university education, university education with
research qualifications, unknown). The Danish National Patient Register provided informa-
tion on diagnosis of polycystic ovary syndrome (yes/no) or endometriosis (yes/no). All models
were adjusted for these conditions since women with these diseases more often use hormonal
contraception.
Hormonal contraceptive use and risk of pancreatic cancer
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Analysis
Data was analyzed by Poisson regression using SAS statistical software, version 9.1 (SAS Insti-
tute, Inc., Cary, North Carolina) to calculate incidence rate ratios (referred to as relative risk)
and 95% confidence intervals. Age was used as a timescale in the Poison regression analyses
with 5-year age bands. The study population was followed until a first diagnosis of pancreatic
cancer, death, emigration, 50 years of age, or end of follow-up on December 31, 2014, which-
ever came first. Women were censored permanently at time of cancer diagnosis, infertility
treatment, or venous thrombosis. Women were censored temporarily during pregnancy and
for six months after delivery.
The following time-dependent variables were updated daily: hormonal contraception vari-
ables, age, calendar year, parity, age at first birth, and education. The simple adjusted models
included hormonal contraception, age, and calendar year. Calendar year was included to
account for possible changes in the use of specific types of contraception and in pancreatic
cancer incidence during the study period. The fully adjusted models included all the time-
dependent and the time-constant variables; polycystic ovary syndrome (ever), and endometri-
osis (ever). Additional adjustment for body mass index and smoking status and the time of
first birth was conducted among parous women with this information. The reference group in
each analysis was women who had never used hormonal contraception at a given time during
follow-up. Calculated risk ratios will be referred to as relative risks throughout the manuscript,
this includes all tables.
A search of the PubMed database was performed where relevant articles were identified
using the following search terms: “pancreatic cancer”, “pancreatic adenocarcinoma”, “pancre-
atic neoplasm” combined with “reproductive factors”, “oral contraception”, “exogenous hor-
mone use”. Date of last search was on the 1st of February 2018. A flow chart further describing
the inclusion of studies can be found in the supporting information. (S1 Fig).
Approval
Data was made available through Statistics Denmark and approval obtained from the Danish
Data Protection Agency and Health Data Board (previous National Board of Health). Accord-
ing to the Danish Research Ethics Committee Law (§ 8, section 3), ethical approval is not
required for register-based studies. Data must be requested from the Danish National eHealth
Authority due to legal restrictions on sharing data publicly. Data requests are sent through the
application form at: https://sundhedsdatastyrelsen.dk/da/forskerservice/ansog-om-data (the
website is in Danish).
Results
From 1995 to 2014 women aged 15–49 years old accumulated 12.9 million person-years of
hormonal contraceptive use and 235 pancreatic cancers incidents were recorded.
Compared to never users, ever users of any type of hormonal contraception had a relative
risk of pancreatic cancer of 0.90 (95% confidence interval (CI) 0.68–1.19) (Table 1).
Current or recent users of any type of hormonal contraception had a relative risk of 1.01
(95% CI 0.72–1.42). No overall association between duration of hormonal contraception use
and pancreatic cancer risk was found (Table 1). Neither was long-term use (more than 10
years) of hormonal contraception associated with cancer of the pancreas: relative risk 0.83
(95% CI 0.47–1.50). Compared to never use, former users had a relative risk of 0.80 (95% CI
0.57–1.13), not significantly changing with time since latest use (Table 1).
Compared to never users, current or recent use of progestin only contraception showed a
relative risk of 1.16 (95% CI 0.79–1.89) and combined oral contraception a relative risk of 0.92
Hormonal contraceptive use and risk of pancreatic cancer
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(95% CI 0.62–1.36) (Table 2). The simple and fully adjusted results were almost identical.
Additional adjustment for smoking status and body mass index in parous women did not
change the estimates.
Discussion
In accordance with most of the current evidence we found no association between hormonal
contraception use and pancreatic cancer risk [9–13,17,19,20](S1, S2 and S3 Tables). Neither
was long-term use associated with risk of pancreas cancer which is in contrast to the sugges-
tion by one previous cohort study [3].
The exposure of both exogenous estrogens and endogenous estrogens (i.e. parity and meno-
pause) and risk of pancreatic cancer have been explored in epidemiological studies and results
are not consistent [8][19]. A systematic review of several case-control and cohort studies con-
cludes, that reproductive factors have no association with the development of pancreatic can-
cer in women [19]. However, anti-estrogens such as tamoxifen have been observed having an
inhibitory effect on the early stages of pancreatic carcinogenesis [21]. Some cases of unresect-
able liver metastasis of pancreatic cancer have shown favorable prognosis after being treated
with tamoxifen, an anti-estrogen drug. These were solid pseudopapillary neoplasms a low-
grade malignant pancreatic tumor comprising 0.9% to 2.7% of all pancreatic malignancies.
Solid pseudopapillary neoplasms occur predominantly in premenopausal women and there-
fore female sex-hormones have been presumed to be associated with the development and
growth of these tumors. However, clinical trials with tamoxifen in pancreas cancer have not
shown therapeutic effect [19].
Table 1. Relative risk of pancreatic cancer in premenopausal women according to length of hormonal contraceptive use.
Hormonal Contraception Person years Cancer events Relative risk� 95% Confidence Interval
Never use 8,109,998 139 1 Reference
Ever use 12,905,304 115 0.90 0.68 1.19
Previous use (>6 months ago) 4,873,757 58 0.80 0.57 1.13
Current or recent use 8,031,547 57 1.01 0.72 1.42
Duration of current use
< 5 years 4,391,494 26 1.21 0.78 1.88
5–10 years 2,434,211 16 0.91 0.53 1.57
>10 years 1,205,842 15 0.83 0.47 1.50
Time since last use
< 5 years 3,296,650 27 0.74 0.48 1.13
5–10 years 1,109,695 20 0.93 0.57 1.53
>10 years 474,230 11 0.78 0.41 1.51
� Adjusted for age, year, education, PCOS, endometriosis, and parity.
https://doi.org/10.1371/journal.pone.0206358.t001
Table 2. Relative risk of pancreatic cancer in users of different types of hormonal contraception.
Hormonal contraception Person-years Cancer events Relative risk� 95% Confidence Interval
Never use 8,109,998 139 1 Reference
Oral combined 20–40 ug EE 6,915,192 36 0.92 0.62 1.36
Progestin only 994,686 21 1.16 0.71 1.89
�Adjusted for age, year, education, PCOS, endometriosis, and parity.
https://doi.org/10.1371/journal.pone.0206358.t002
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No prior study has assessed the risk of pancreatic cancer with progestin-only products in
pre-menopausal women. We found no influence on risk of pancreas cancer with use of these
products.
Limitations
We were not able to adjust for alcohol consumption and dietary factors [19][22]. If women on
hormonal contraception have higher alcohol consumption than never-users, we would have
overestimated the risk of pancreas cancer associated with current or recent use of hormonal
contraception. However, since our risk estimates were not adjusted for these factors, hormonal
contraceptive use is unlikely to increase the risk of pancreas cancer; if anything, these factors
might have biased a potential decreased risk with hormonal contraception use. We cannot be
sure that residual confounding or unknown confounders could influence the results. If our
results are biased it would most likely imply that we had failed to notice a protective effect of
hormonal contraception which would be contradictory to other studies which have explored
the same association.[23][11][10] Finally, redeemed prescriptions of medication are not neces-
sarily taken. Repeat prescriptions account for of most of the exposure history, and thus this
potential misclassification of exposure is unlikely to have influenced our results.
Strengths
Our study adds to the sparse evidence on the influence of newer hormonal contraceptive prod-
ucts on the pancreatic cancer risk in women of reproductive age. Our nationwide study is a
large-scale prospective cohort study with 1.9 million Danish women followed for an average of
more than ten years. We had complete follow-up until diagnosis of cancer, venous thrombosis,
infertility treatment, emigration, death or end of study. The validity of pancreatic cancer diag-
noses is high because the Danish Cancer Register cross-check their records with histology rec-
ords to ensure both a high level of completeness and validity of diagnoses. [24,25][26]
The validity of exposure is also likely to be high in our study because recall bias has been
eliminated. Information about redeemed hormonal contraception prescriptions is transferred
electronically from the pharmacies using bar codes. Thus, we were able to account for switch
in use and cessation of use. Our information about both exposure and relevant confounders
was updated daily. Information about hormonal contraception and pancreatic cancer was
recorded in the relevant national registers without the intention of exploring the association
between hormonal contraceptive use and clinical outcomes known, making differential ascer-
tainment of exposure and cancer incidence unlikely.
Our results were adjusted for age, year, educational attainment, number of births, endome-
triosis, and polycystic ovary syndrome. Additionally, for parous women, smoking and BMI.
Adjustment for smoking and BMI did not change our estimates noticeably indicating no
major confounding influence of these factors.
The novelty of this study is based upon the quality and quantity of our data utilized for our
analysis. This dataset is unprecedented compared to other studies in this area and our focus
has solely been on premenopausal women. It is reassuring that we do not find an increased
risk of pancreatic cancer in premenopausal women using hormonal contraceptives due to the
serious nature of the disease and high mortality rate.
Conclusion
In conclusion our study suggests no risk of pancreatic cancer with use of any type of hormonal
contraception in premenopausal women. Thus, the risk of pancreatic cancer is not a factor to
be considered when assessing the risks and benefits of hormonal contraceptive use.
Hormonal contraceptive use and risk of pancreatic cancer
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